PMID- 25303153 OWN - NLM STAT- MEDLINE DCOM- 20150629 LR - 20220408 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 9 IP - 10 DP - 2014 TI - The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PG - e108844 LID - 10.1371/journal.pone.0108844 [doi] LID - e108844 AB - Postprandial hyperglycemia induces inflammation and endothelial dysfunction resulting in vascular complications in patients with diabetes. Toll-like receptors (TLRs) are central to the regulation of inflammatory responses through activation of nuclear factor-kappa B (NF-kB). This study examined the role of TLR2 and 4 in regulating inflammation and endothelial dysfunction when exposed to fluctuating glucose concentrations. HMEC-1 cells (a human microvascular endothelial cell line) were exposed to control (5 mM), 30 mM (high), fluctuating (5/30 mM) and 11.2 mM glucose (approximate glycaemic criteria for the diagnosis of diabetes mellitus) for 72 h. Cells were assessed for TLR2, 4, high mobility group box -1 (HMGB1), NF-kB, monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Fluctuating glucose concentrations maximally upregulated TLR4 but not TLR2 expression with increased NF-kB activation, IL-8 and ICAM-1 expression. HMGB1 was increased in the supernatants of cells exposed to 30 mM and 11.2 mM glucose compared to control. The addition of recombinant HMGB1 induced NF-kB activation and synthesis of proinflammatory cytokines and chemokines, which were prevented by TLR2 or 4 signalling inhibition. An additive effect when both TLR2 and 4 signalling pathways were inhibited was observed. However, only inhibition of TLR4 signalling suppressed the synthesis of MCP-1, IL-8 and ICAM-1. In vivo, streptozotocin-induced diabetic mice exhibited an increase in glomerular ICAM-1 which was not evident in TLR2(-/-) or TLR4(-/-) diabetic mice. Collectively, our results suggest that targeting the signalling pathway of TLR2 and 4 may be of therapeutic benefit in attenuating vascular inflammation in diabetic microangiopathy. FAU - Mudaliar, Harshini AU - Mudaliar H AD - Renal Research Group, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia. FAU - Pollock, Carol AU - Pollock C AD - Renal Research Group, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia. FAU - Ma, Jin AU - Ma J AD - Renal Medicine Royal Prince Alfred Hospital and Collaborative Transplant Research Group, University of Sydney, Camperdown, New South Wales, Australia. FAU - Wu, Huiling AU - Wu H AD - Renal Medicine Royal Prince Alfred Hospital and Collaborative Transplant Research Group, University of Sydney, Camperdown, New South Wales, Australia. FAU - Chadban, Steven AU - Chadban S AD - Renal Medicine Royal Prince Alfred Hospital and Collaborative Transplant Research Group, University of Sydney, Camperdown, New South Wales, Australia. FAU - Panchapakesan, Usha AU - Panchapakesan U AD - Renal Research Group, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141010 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Toll-Like Receptor 2) RN - 0 (Toll-Like Receptor 4) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Cell Line MH - Diabetes Mellitus, Experimental/genetics/*immunology/pathology MH - Endothelial Cells/*immunology/pathology MH - Gene Deletion MH - Glucose/*immunology MH - Humans MH - Inflammation/genetics/immunology/pathology MH - Intercellular Adhesion Molecule-1/immunology MH - Mice, Inbred BALB C MH - Signal Transduction MH - Toll-Like Receptor 2/genetics/*immunology MH - Toll-Like Receptor 4/genetics/*immunology PMC - PMC4193767 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2014/10/11 06:00 MHDA- 2015/06/30 06:00 PMCR- 2014/10/10 CRDT- 2014/10/11 06:00 PHST- 2014/04/29 00:00 [received] PHST- 2014/09/05 00:00 [accepted] PHST- 2014/10/11 06:00 [entrez] PHST- 2014/10/11 06:00 [pubmed] PHST- 2015/06/30 06:00 [medline] PHST- 2014/10/10 00:00 [pmc-release] AID - PONE-D-14-19298 [pii] AID - 10.1371/journal.pone.0108844 [doi] PST - epublish SO - PLoS One. 2014 Oct 10;9(10):e108844. doi: 10.1371/journal.pone.0108844. eCollection 2014.